Web-Casey_Cunningham-8172-Edit- (Zoom)

Casey Cunningham, MD Chief Scientific Officer

Casey Cunningham, MD is the Chief Scientific Officer of Santé Ventures. Dr. Cunningham received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. He completed fellowship training in oncology and hematology at Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women’s Hospital in Boston. Casey returned to Texas in 1999 as the Associate Director of the Mary Crowley Cancer Research Center in Dallas, a position he held until 2007. He joined Santé Ventures shortly after its founding. He has served in operating roles in Terapio, Molecular Templates, and Iterion Pharmaceuticals and has been, or is currently on, the Boards of Terapio Corp., Molecular Templates, Lyric Pharmaceuticals, AbVitro, Mirna Therapeutics, Geneos Therapeutics, and Glyscend. Casey is also on the National Board of the Leukemia and Lymphoma Society and is the Chair of their Therapy Acceleration Program.

News
March 18, 2020 NewLink Genetics Stockholders Approve Merger with Lumos Pharma
Read More
February 25, 2020 BioStable Science & Engineering Announces Initial Closing of Series C Equity Round
Read More